logo
Twitter
Discord
Email
logo
logo
Savara Inc.NASDAQ - SVRA
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-12
2024-06-30 10-Q2024-06-302024-08-12
2024-03-31 10-Q2024-03-312024-05-09
2023-12-31 10-K2023-12-312024-03-07
2023-09-30 10-Q2023-09-302023-11-09
2023-06-30 10-Q2023-06-302023-08-10
2023-03-31 10-Q2023-03-312023-05-15
2022-12-31 10-K2022-12-312023-03-30
2022-09-30 10-Q2022-09-302022-11-10
2022-06-30 10-Q2022-06-302022-08-11
2022-03-31 10-Q2022-03-312022-05-11
2021-12-31 10-K2021-12-312022-03-30
2021-09-30 10-Q2021-09-302021-11-12
2021-06-30 10-Q2021-06-302021-08-12
2021-03-31 10-Q2021-03-312021-05-13
2020-12-31 10-K2020-12-312021-03-10
2020-09-30 10-Q2020-09-302020-11-05
2020-06-30 10-Q2020-06-302020-08-06
2020-03-31 10-Q2020-03-312020-05-07
2019-12-31 10-K2019-12-312020-03-12
1
2
20 / page
About
Name
Savara Inc.
Overview
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Show More
CEO
Mr. Matthew Pauls J.D., M.B.A.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2017-04-28
Address
1717 Langhorne Newtown Road, Suite 300, Langhorne, PA, 19047, United States
Tel
512-614-1848
Website
https://www.savarapharma.com